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Abstract
Motivation: COVID-19 has several distinct clinical phases: a viral replication phase, an inflammatory
phase, and in some patients, a hyper-inflammatory phase. High mortality is associated with patients
developing cytokine storm syndrome. Treatment of hyper-inflammation in these patients using existing,
approved therapies with proven safety profiles could address the immediate need to reduce mortality.
Results: We analyzed the changes in the gene expression, pathways and putative mechanisms induced
by SARS-CoV2 in NHBE, and A549 cells, as well as COVID-19 lung vs. their respective controls. We
used these changes to identify FDA approved drugs that could be repurposed to help COVID-19 patients
with severe symptoms related to hyper-inflammation. We identified methylprednisolone (MP) as a potential
leading therapy. The results were then confirmed in five independent validation data sets including Vero E6
cells, lung and intestinal organoids, as well as additional patient lung sample vs. their respective controls.
Finally, the efficacy of MP was validated in an independent clinical study. Thirty-day all-cause mortality
occurred at a significantly lower rate in the MP-treated group compared to control group (29.6% vs. 16.6%,
p = 0.027). Clinical results confirmed the in silico prediction that MP could improve outcomes in severe
cases of COVID-19. A low number needed to treat (N N T = 5) suggests MP may be more efficacious
than dexamethasone or hydrocortisone.
Availability: iPathwayGuide is available at https://ipathwayguide.advaitabio.com/
Contact: sorin@wayne.edu and gmor@med.wayne.edu
Supplementary information: Supplementary data are available at Bioinformatics online.

1 Introduction
Most current efforts related to COVID-19 span a number of areas as
follows: i) antivirals, ii) vaccine development, iii) diagnostic tests, and
iv) patient-supporting interventions. Without reducing the significance
and impact of any of the areas above, there is an important aspect
1
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2 Approach
We used data from cell lines, cell cultures as well as human patients to
understand the changes induced by the infection with SARS-CoV-2.
We started by analyzing transcriptomic data to compare the A549
lung cell line infected with SARS-CoV-2 vs. mock infection (henceforth
A549CoV2vsControl), A549 infected with seasonal influenza A virus
vs. mock infection (A549IAVvsControl), and A549 infected with human
respiratory syncytial virus vs. mock infection (A549RSVvsControl).
We also compared the transcriptional response in primary human
bronchial epithelial (NHBE) between cells infected with SARS-CoV2
and mock infection (NHBECoV2vsControl). Finally, we compared the
transcriptional response in COVID-19 lung tissues vs. healthy lung tissue
(COVID19vsControl). These data were collected at Mount Sinai and are
available in GEO as the GSE147507 data set (Blanco-Melo et al., 2020).

The motivation behind studying these contrasts was to be able to
differentiate a specific cellular response, as observed when using cell lines,
versus the response of the organism as it is reflected in a particular tissue, as
observed when using patient samples. Also, by comparing the IAV or RSV
infections with the SARS-CoV-2 infection, we can differentiate between
a general response to a viral infection versus a specific response to the
corona virus. The approach used can be summarized as follows:
1. We first used a GO analysis to see what biological processes appear
to be involved in the SARS-CoV-2 infection. This was based first
on an enrichment analysis (Tavazoie et al., 1999; Draghici et al.,
2003) followed by a more sophisticated analysis that takes into
consideration the relationships between the GO terms and eliminates
the redundancy (Alexa et al., 2006). Both were followed by an FDR
correction for multiple comparisons (Benjamini and Hochberg, 1995;
Benjamini and Yekutieli, 2001).
2. We then used a pathway analysis to identify the impacted pathways.
The approach used here, the impact analysis (Draghici et al., 2007;
Tarca et al., 2009b), uses not only the measured fold changes but also
the position of every gene on every pathway, as well as the direction
and type of every signal from one gene to another.
3. This was followed by an upstream analysis aiming to identify any
specific upstream regulators that may play a role in this infection
and/or the immune response to it.
4. The next step was a mechanism inference aiming to identify the
mechanisms likely to be involved on these pathways or linking the
genes involved in the key biological processes identified. This was
based on the pathways and biological processes identified above,
the measured fold changes in the genes participating in these, and
all known protein-protein interactions (PPIs), both from existing
pathways, as well as from known PPIs databases such as STRING.
5. The last step was the drug-target analysis which took the processes,
pathways, and genes identified above and aimed to estimate the ability
of each known drug to reverse the most relevant gene expression
changes induced by the SARS-CoV-2 infection. This step was based
on known interactions between drugs and genes or proteins.
The existing FDA-approved drug that resulted from the process above
was validated in five additional independent datasets coming from different
laboratories, as well as in a clinical study.

3 Results
3.1 Disrupted genes and biological processes.
We evaluated the biological processes that are affected by SARS-Cov2 in lung epithelial cells. We performed a comparison of the affected
biological processes in COVID19vsControl, NHBECoV2vsControl,
A549CoV2vsControl, A549IAVvsControl, and A549RSVvsControl
(Fig. S1). The biological processes (BPs) are shown ordered by their
significance in COVID19vsControl. In spite of a larger number of
differentially expressed (DE) genes in the SARS-Cov-2-infected lung
(815), there are only 7 significant biological processes involved, which
may indicate a more coordinated, systemic response. In contrast, the
changes in the NHBE cells are characterized by fewer DE genes (only
223) but span more uncoordinated biological processes. This is illustrated
in Fig. S2 which shows the BPs ordered in the order of significance from
NHBECoV2vsControl.

3.2 Putative mechanisms of disease.
We performed an analysis aiming to identify putative mechanisms of
disease. As part of this analysis we identified four genes that were predicted
to be activated upstream regulators based on the observed changes in
their downstream genes. These were IRF9, STAT2, IFNG, and IFNB1.
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that has not been elucidated: the identification and treatment of patients
developing critical conditions and risk of mortality. Recently, Mehta
et al. stated that “Accumulating evidence suggests that a subgroup of
patients with severe COVID-19 might have a cytokine storm syndrome”
that correlates with high mortality (Mehta et al., 2020). Therefore,
identification and appropriate management of the patients developing
cytokine storm syndrome is critical for successful outcomes. Treatment
of hyper-inflammation in these patients using existing, approved therapies
with proven safety profiles could address the immediate need to reduce the
rising mortality.
COVID-19 has several distinct clinical phases: an infection phase, a
viral replication phase, an inflammatory phase, and in some patients, a
hyper-inflammatory phase or cytokine storm (Siddiqi and Mehra, 2020;
Ayres, 2020). After the initial viral phase of the illness, some patients
will develop a cytokine storm which has being associated with the acute
respiratory distress syndrome (ARDS) and mortality. Therefore, in order to
decrease the risk of mortality is necessary to distinguish the phase where
the viral pathogenicity is dominant versus when the host inflammatory
response overtakes the pathology (Siddiqi and Mehra, 2020; Ayres, 2020).
A potential approach is to develop interventions that could inhibit/prevent
the hyper-inflammatory process leading to the cytokine storm. A strong
argument in favor of also targeting the host response is offered by the data
on influenza. Even though influenza patients receive optimal anti-viral
therapy, approximately 25% of the critically ill influenza patients still
die (Ayres, 2020; Louie et al., 2012). This suggests that anti-viral therapy
alone will not be sufficient for COVID-19 either, and the host response to
the virus still needs to be taken into consideration.
However, approaches aiming at modulating the immune response
face some concerns. In particular, it may seem counter-intuitive to try
to diminish the immune response in a patient whose immune system
is fighting against a virus. Modulating the immune system is likely
unnecessary and counter-productive for patients whose immune system is
doing a good job at resolving the infection, while it could potentially be lifesaving for those whose inflammatory response has become dysregulated.
If a patient has developed severe respiratory symptoms and is hypoxic,
the host response that lead to ARDS, sepsis, and organ failure has already
been initiated (Mehta et al., 2020). At this point, the focus should shift
to supporting the patient’s systems and preventing collapse triggered by
hyper-inflammation (Ayres, 2020).
In order to identify the best potential therapeutic approach, we
performed a transcriptome analysis of tissues and cell samples infected
with SARS-CoV-2 in order to understand the main mediators of the
inflammatory process. Once characterized the inflammatory pathways we
identified drugs that would mitigate or alleviate some of the devastating
over-reactions of the host’s immune system (e.g. cytokine storm). Finally,
we evaluated the efficacy of the identified drug in a small cohort of
COVID-19 patients.
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These suggest two different potential mechanisms. The first appears to be
triggered by STAT2 and IRF9, which have 16 common target genes that
are also all significantly up-regulated (IFI6, IFIT1, IFIT2, IFIT3, IFITM1,
IFITM3, OAS1, OAS3, OAS S32, MX1, MX2, RSAD2, OASL, XAF1,
IRF2, and IRF7). This mechanism is also known to be involved in the
response to influenza A (see influenza A pathway in Fig. S4).
The second putative mechanism involves interferon beta and gamma,
which are targeting 5 common downstream genes: CXCL10, IDO1,
DOX58, STAT1, which are up-regulated, and HMOX2 which is downregulated. Interferon regulatory factors (IRFs) are subdivided into the
interferonic IRFs (IRF2-3-7 and 9), the stress responsive IRFs (IRF1
and 5), the hematopoietic IRFs (IRF4 and 8) and morphogenic IRF6.
IRF9 is a regulator of type I IFN signaling and is known to interact
with STAT2 (Horvath et al., 1996) and STAT1 to form the heterotrimeric
transcription factor complex (ISGF3) that binds to interferon-stimulated
response elements (ISREs) to induce the expression of interferon
stimulated genes (ISG). During viral infections, ISGs perform two key
functions: 1) directly limit viral replication by shutting down protein
synthesis and triggering apoptosis; 2) activate key components of the
innate and adaptive immune system, including antigen presentation
and production of cytokines. The genes triggered by the STAT2 and
IRF9 pathway include genes responsible for limiting viral replication
(IFI6, IFIT1, IFIT2, IFIT3, IFITM1, IFITM3, OAS1, OAS3, OAS2,
MX1, MX2, RSAD2, OASL) and inducers of apoptosis (XAF1, IRF2,
IRF7). CXCL10, IDO1, DOX58, and STAT1 are genes associated with
lymphocyte recruitment and immune regulation.
Interestingly, STAT2 and IRF9 together are also identified as
activated upstream regulators due to 15 downstream targets even in the
NHBECoV2vsControl (see Fig. S5). However, in the NHBE cells, the

interferon activators were replaced by an interleukin based mechanism
centered around IL1B, IL6, IL17A, adiponectin (ADIPOQ) and tumor
necrosis factor (TNF).
We also looked at genes that are known to modulate or inhibit
the inflammatory response such as IL1RN IL10, and IL13. In the
COVID19vsControl, IL1RN was up with a log2 fold change of 6.2 fold
(a 78-fold increase, FDR-corrected p = 10−6 ), IL10 was up 2.8 fold
(FDR-corrected p = 0.55), while the measurement for IL13 was not
available. In the NHBECoV2vsControl, IL1RN was up only 1.26 fold
(FRD-corrected p = 0.035), while measurements for IL10 and IL13
were not available. However, in this contrast, 14 out of 15 DE genes
immediately downstream of IL10 and usually inhibited by IL10 were upregulated which strongly supports the hypothesis that IL10 is inhibited
(FDR-corrected p = 5.17 × 10−9 ).

3.3 Impacted pathways.
The significantly impacted pathways are shown in Fig. S6 and
Fig. S7 ordered by their significance in COVID19vsControl and
NHBECoV2vsControl, respectively. The p-values represent a combination
of enrichment and perturbation p-values (Draghici et al., 2007)
subsequently corrected with FDR (see Supp. Materials for details).
Fig. 1 shows the most impacted pathway, the Cytokine-cytokine
interactions. The gene expression changes on this pathway show a very
large number of pro-inflammatory cytokines and cytokine receptors being
up-regulated, while several of the anti-inflammatory genes in the TGFbeta family are down-regulated. This corroborates the GO analysis finding
above that there is a very strong positive regulation of inflammatory
response.
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Fig. 1: The cytokine-cytokine receptor interactions pathway is the most significantly impacted pathway in COVID19vsControl and the second most
impacted in NHBECoV2vsControl. This is due mainly to the large number of dis-regulated cytokines. The image shows up-regulated genes (red), downregulated genes (blue), as well as genes that are targeted by existing FDA-approved drugs (in ovals). Note that all up-regulated genes are pro-inflammatory
while the down-regulated genes are anti-inflammatory, supporting the idea that the severe symptoms may be caused by a cytokine storm.
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Fig. 2 shows the Chemokine signaling pathway. On this pathway, the
impact is due both to the large number of DE genes (26 out of 130),
as well as to the clear signal propagation from the chemokines outside
the cell (11 chemokines up-regulated), through the chemokine receptor
and via the JAK and STAT mechanism. Note that the same mechanism
is also identified on the Influenza A pathway shown in Fig. S4 in the
Supplementary Materials. Fig. S9 shows another view of the mechanism
involving the genes on this pathway and all their known interactions.
Together, the GO analysis, pathway analysis and the putative
mechanisms identified by the analysis above strongly suggest a hyperinflammation/cytokine storm.

3.4 Screening of potential therapeutic approaches:
Proposed drugs.
Once we identified the main regulatory pathways potentially associated
with hyper-inflammation, we evaluated in silico FDA-approved drugs
that could show activity on multiple components of inflammation and
consequently could be used for the management of severe COVID-19
cases. We considered the number of DE genes that would be reverted by
each drug, as well as calculated a Bonferroni-corrected p-value indicating
the suitability of each drug for repurposing in COVID-19 based on
two different approaches (see “Methods” section). We looked for drugs
that have both small Benforroni-corrected p-values as well as revert a

larger number of DE genes. The top five drugs drug identified by our
analysis are shown in Fig. 3. Methylprednisolone (MP) and prednisolone
are corticosteroids currently used to modulate the immune response in
rheumatoid arthritis. Diclofenac is a non-steroidal anti-inflammatory drug
(NSAID). Tofacitinib is a JAK inhibitor (see the JAK-STAT mechanism
identified in Fig. 2). Gold sodium thiomalate is an older anti-inflammatory
drug, also used in the treatment of rheumatoid arthritis.
Methylprednisolone (MP) is the drug that was identified as the most
likely to work by inhibiting the inflammatory pathway. This drug targets
27 genes that are found to be DE in COVID19vsControl. Out of these 27
genes, the drug would revert the changes in 25 of them. The drug also
had an extremely significant p-value even after a Bonferroni correction
which is the most stringent correction available (p = 5.72 × 10−10 ). MP
also reverted 22 out of 22 genes found to be DE in NHBECoV2vsControl,
and 25 out of 26 genes found to be DE in A549CoV2vsControl. Fig. 4
shows the putative mechanism through which MP acts on the DE genes in
COVID19vsControl, and how these genes influence the BPs found to be
significantly impacted.

3.5 Validation on independent data sets
The initial results obtained on from the data above were subsequently
confirmed using additional data, spanning again all three types of samples:
cell lines, tissue cultures, and patient samples. The additional cell line data
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Fig. 2: The chemokine signaling pathway is the second most significantly impacted pathway in COVID19vsControl. The red arrows represent chains of
coherent perturbation propagation, i.e. sequence of steps for which the observed expression changes are coherent with the expected changes according to
the phenomena described by the pathway. The node labelled “chemokines” represents 11 chemokines measured to be up-regulated (CCL2, CCL3, CCL4,
CCL7, CCL8, CCL11, CCL18, CCL19, CXCL10, CXCL11, CXCL16 ). The CCR1 receptor is also up-regulated, as well as JAK3 and STAT1. The ovals
represent drug targets for which FDA-approved drugs already exist. On this pathway, the impact is due both to the large number of DE genes (26 out of
130), as well as to the signal propagation as shown by the red arrows.
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include data from Vero E6 cells infected with SARS-CoV-2 vs. controls.
Additional tissue cultures include lung organoids infected with SARSCoV-2 vs. controls. In addition, even though the SARS-CoV-2 virus
is primarily thought to infect the lungs with transmission through the
respiratory route, it has been suggested that the intestine may present
another viral target organ (Lamers et al., 2020). For this reason, we
also compared the expression profiles of intestine organoids infected with
SARS-CoV-2 vs. mock infection in differentiation and expansion media.
These data are available in GEO as the GSE153940 (Vero E6 cells) (Riva
et al., 2020), GSE160435 (lung organoids), and GSE149312 (intestinal
organoids) (Lamers et al., 2020) data sets.
Finally, twenty nine additional samples from the lung of deceased
COVID-19 patients with a high viral load and five controls were included
from the Massachusetts General Hospital and Columbia University Irving
Medical Center. These are available in GEO as the GSE150316 data
set (Desai et al., 2020).
Fig. S10 in Supplementary Materials show the biological processes
common across the five additional independent data sets according to the
the classical enrichment analysis. All of these are consistent with a viral
response. In particular, the Type I interferon pathway is significant in every
single data set analyzed, both initially, as well as in the additional validation
data sets. The upstream regulators identified in the initial analysis, STAT2
and IRF9, were also found to be significant up-stream regulators in every
single validation data set (see Fig. S11).
Fig. S12 shows existing FDA-approved drugs identified as suitable
candidates for repurposing based on these five additional data sets. These
additional and independent data sets span across cell lines, cell cultures
and patient data, as detailed above. Note that the top five drugs obtained
on these additional data sets are matching perfectly with those shown in
Fig. 3 even though the data sets analyzed were completely independent.

3.6 In vivo effect of methylprednisolone: Clinical validation.
In an independent study, 213 patients diagnosed with COVID-19 were
enrolled. 81 (38%) received conventional therapy (control group) while
132 patients (62%) received MP (MP group). The clinical characteristics
and treatments received by the patients are shown in Table S2 and Table S3,
respectively. As shown in Table S4 thirty day all-cause mortality occurred
at a significantly lower rate in the MP group compared to control group
(29.6% vs. 16.6%, p = 0.027). No statistical difference was detected
in the proportion of patients prescribed empiric antibiotics or the time
to empiric therapy. Kaplan Meier survival curve for 30-day mortality

Fig. 4: The putative mechanism through which MP acts on the genes
measured to be DE, and how these genes influence the biological processes
found to be significantly impacted in the COVID19vsControl. This figure
shows that: i) MP is known to revert the measured changes in all these 21
DE genes; ii) 20 out of these 21 DE genes are up-regulated suggesting a
very strong immune response; ii) many of the DE gene targeted directly
by MP are directly involved in the top biological processes identified as
significantly perturbed by the disease.

demonstrated increased probability of survival at 30-days in the MP group
as compared to the control group (p = 0.0204) (Fig. 5).
When comparing the two groups, those patients treated with a 3-day
methylprednisolone protocol spent less time in the hospital (5 vs 8 days)
and were less likely to be admitted to the ICU (27% vs 44%), being placed
on a ventilator (22% vs 37%) or dying (14% vs 26%).
For a composite end point of preventing ICU admission, need for
mechanical ventilator or mortality, the number needed to treat (NNT) to
benefit a single patient was only 5 when methylprednisolone was used
early in hospitalization. To prevent mortality, the NNT to benefit a single
patient was only 8 for all hospitalized patients. This is in contrast to the
RECOVERY trial (NCT04323592) for dexamethasone, where NNT was 8
for patients on mechanical ventilation and 25 for patients needed oxygen
to prevent mortality.

3.7 Other drugs investigated.
We also looked at other drugs that have already been proposed
as repurposing candidates for COVID-19 including: chloroquine,
hydroxychloroquine, erythromycin, prednisone, dexamethasone,
ibuprofen, ritonavir, aspirin, and clopidogrel. Most or all of these drugs
are currently under clinical trials (Sanders et al., 2020).
Chloroquine was found to revert only 2 out of 4 genes found to be
differentially expressed in the COVID19vsControl (p = 1) and only 3 out
of 6 genes found to be differentially expressed in NHBECoV2vsControl
only (p = 1). Furthermore, this drug was not found to be potentially
effective in reversing the changes in A549RSVvsControl (p = 1) or
A549CoV2vsControl (p = 1). These results suggest that chloroquine
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Fig. 3: The top five drugs proposed for repurposing. The table shows both
p-values corrected with Bonferroni, as well as the number of DE genes
that would be reverted out of the total number of DE genes immediately
downstream of each drug (annotated as “consistent (-)/DE targets" in
the table). Methylprednisolone (MP) and prednisolone are corticosteroids
currently used to modulate the immune response in rheumatoid arthritis.
Gold Sodium Thiomalate is an older drug, not currently in use in the US.
Diclofenac is a NSAID and tofacitinib is a JAK inhibitor. The column for
A549IAVvsControl is empty because there are no DE genes targeted by
these drugs in this contrast.
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would not be a good potential candidate for repurposing for the goal of
modulating the immune response.
Hydroxychloroquine did not appear as a good candidate for
repurposing in any of the phenotypes and contrasts studied here.
Chloroquine and hydroxychloroquine do not target any of the 21 genes
that are both severely dysregulated, and also targeted by the proposed
drugs. Note that while these drugs do not reverse observed gene expression
changes, they may act as anti-virals by potentially inhibiting the viral
replication (Sanders et al., 2020).
Erythromycin targets only three DE genes in COVID19vsControl
and would revert only 2 of those. This yields an insignificant p value
(Bonferroni-corrected p = 1 and FDR-corrected p = 0.75).
Ibuprofen was also not found to be a good candidate for use in COVID19, having the potential to revert only 4 out of 10 DE genes (p = 1). This
suggests a phenomenon in the class of NSAIDs similar with that observed
within the corticosteroids: while one or two specific drugs may be effective,
these effects cannot be generalized to the entire class. In other words, not
all NSAIDs may be equally helpful in modulating the over-inflammation
induced by COVID-19.
Ritonavir was found to be significant (p = 0.002) in reverting changes
in 8 out of its 10 targets that were measured to be differentially expressed
in NHBECoV2vsControl. However, ritonavir was not found to be effective
in reversing the gene changes induced in COVID19vsControl.
Clopidogrel targets only one DE gene in COVID19vsControl, one DE
gene in A549CoV2vsControl, and no DE gene in NHBECoV2vsControl.
These results suggest that this drug is unlikely to be effective in COVID-19
with a p-value of 1 across all experiments.
Finally, aspirin is targeting 44 DE genes in COVID19vsControl but
reversing only 22 of them. In NHBECoV2vsControl samples, aspirin was
found to target 18 genes and revert 12 on them. In NHBE, aspirin has a raw
p-value of 0.028 but after an FDR correction this becomes 0.187. In the
COVID19vsControl contrast, even the raw p-value is 0.939 and becomes
1 after any correction.

4 Discussion
In the present study we described an initial characterization of the main
pro-inflammatory pathways induced by SARS-Cov-2 infection on human
lung epithelial cells and the identification of the most effective therapeutic
approach to inhibit this cytokine storm.
In this study we have identified MP as the most effective, FDA
approved, drug that targets critical components of the inflammatory
pathway responsible for ARDS. Furthermore, we demonstrated its efficacy
in a clinical trial in which MP decreased the incidence of mortality
in COVID-19 patients. An important finding of this study is that
drugs in the same class might not necessarily have similar effects.
For instance, MP and prednisolone were predicted to be effective in
reverting many of the changes triggered by COVID-19, while other
closely-related corticosteroids such as prednisone were not. MP and
prednisolone are corticosteroids currently used to modulate the immune

response in rheumatoid arthritis. Interestingly, we observed that the
putative mechanisms through which these drugs would revert the genes
dysregulated in COVID-19 are different (Fig. 6). MP for example inhibits
STAT1, IFT3 and HERC5 while prednisolone has an impact on IFIT genes
such as IFT1, IFIT3, IFI6, and IFI4L.
We also looked at other corticosteroids such as prednisone, and
hydrocortisone. However, prednisone was found to target only 3
DE genes in the COVID19vsControl and only 2 DE genes in the
NHBECoV2vsControl. From those, prednisone would revert only 1 of
the 3 DE genes in the COVID19vsControl and 0 out of 2 DE genes in the
NHBECoV2vsControl. Both yielded insignificant Bonferroni-corrected pvalues (p = 1) suggesting that prednisone is not expected to be a highly
effective treatment. Prednisolone, dexamethasone, and hydrocortisone
belong to the same family of corticosteroid anti-inflammatory agents and
there is also a structural similarity between them (Fig. S13). In spite of this
structural similarity, hydrocortisone is known to revert only 8 out of 10
DE genes in the COVID19vsControl (FDR-corrected p = 0.57) and 5 out
of 8 DE genes in the NHBECoV2vsControl (FDR-corrected p = 0.038,
Bonferroni-corrected p = 1). Dexamethasone was found to revert 33 out of
69 DE genes in the COVID19vsControl (FDR-corrected p = 1) and 27 out
of 45 DE genes in the NHBECoV2vsControl (FDR-corrected p = 0.002,
Bonferroni-corrected p = 0.066). Dexamethasone is significant in the
NHBECoV2vsControl but not in the COVID19vsControl. Hydrocortisone
appears as significant in COVID19vsControl, but only marginally so in the
NHBECoV2vsControl.
Such differences between drugs in the same class can be potentially
explained in two ways. First, different drugs can be associated with a
different number of annotations. For instance, the number of genes that
a given drug is known to be targeting can influence its significance.
Table S1 in Supplementary Materials shows the number of known targets
associated with some drugs relevant to COVID-19. Second, there could be
genuine differences between the effectiveness of different corticosteroids,
potentially due to a different number of genes truly impacted by each
drug. The results of these study, based on all annotations available to date,
suggest that MP would revert the largest number of the gene perturbed by
COVID-19, followed by dexamethasone and, as shown in the outcome
of COVID-19 infected patients, have a major impact on their clinical
outcome. Prednisone and hydrocortisone revert much fewer known genes
and consequently, could have an effect but it is expected to be less effective
than the one observed with MP. Future clinical trials comparing the efficacy
of these different corticosteroids are necessary to confirm our findings
The host inflammatory response in the lungs lead to acute lung
injury and ARDS. This constitutes the main rationale for the use of
corticosteroids. However, administration of corticosteroids is associated
with multiple side effects, such as an increased risk of secondary infection
and delayed viral clearance. A recent article in Lancet reports that clinical
evidence does not support corticosteroid treatment for COVID-19 (Russell
et al., 2020). However, this report looks at corticosteroids as an entire class
of drugs. A recent retrospective study of 201 patients with COVID-19 in
China found that treatment with MP for those who developed ARDS was
associated effective in decreasing the risk of death. Among patients with
ARDS, treatment with MP decreased the risk of death (HR, 0.38; 95%
CI, 0.20-0.72). In this study, 23 of 50 [46%] patients with MP treatment
died compared to 21 deaths out of 34 patients without MP treatment (Wu
et al., 2020a). Both reports are entirely consistent with our findings:
corticosteroids in general are NOT expected to help as a class of drugs,
but rather each steroid should be assessed individually.
Methylprednisolone has been also the focus on several other recent
clinical studies. Wu et al. studied the effect of MP in a cohort of 201
COVID-19 patients, of which 84 developed ARDS (Wu et al., 2020b).
They report that “among patients with ARDS, treatment with MP decreased
the risk of death (HR, 0.38; 95% CI, 0.20-0.72).” The percentage of people
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Fig. 5: Kaplan Meier survival curve for 30-day mortality demonstrating
increased probability of survival at 30-days in the post methylprednisolone
cohort as compared to the pre-methylprednisolone cohort (p= 0.0204).
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5 Methods

Fig. 6: The putative mechanisms through which methylprednisolone would
revert the changes triggered by COVID-19 in the lung tissue.

who developed ARDS and eventually died was reduced from 61.8% (21
of 34) to 46% (23 of 50).
Salton et al. conducted a multi-center, observational study to explore
the association between a prolonged, low-dose of MP and a composite
endpoint including the need for ICU referrals, intubation, or death within
28 days (www.clinicaltrials.gov, NCT04323592) (Salton et al., 2020).
They found that in a cohort of 83 patients treated with MP and 90 controls,
the treatment with MP significantly lowered the hazard of death (71%).
The composite end point was met by 19 vs. 40 (adjusted hazard ratio (HR)
0.41; 95% confidence interval (CI): 0.24-0.72). Transfer to ICU and need
for invasive MV was necessary in 15 vs. 27 (p = 0.07) and 14 vs. 26
(p = 0.10), respectively. By day 28, the MP group had fewer deaths (6
vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive
MV (24.0 +/- 9.0 vs. 17.5 +/- 12.8; p = 0.001).
A similar multi-center study focus on MP was undertaken in Spain
(European Clinical Trials Register: 2020-001934-37). This study involved
85 patients of which 34 were randomized to MP, 22 were assigned to
MP by the clinician and 29 constituted the control group. The composite
endpoint requirement of non-invasive ventilation, admission to ICU, and
death. This study reported that the use of MP was associated with a
reduced risk of the composite endpoint (RR 0.55 95% CI 0.33-0.91)
(https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1).
Finally, preliminary results from a large randomized study undertaken
in the UK (NCT04381936) show that dexamethasone is also able to
significantly reduce the number of deaths. In this study the steroid
group included 2,100 participants and was compared with the standard of
care group including 4,300 participants. Unfortunately, this study placed
dexamethasone in the same arm with MP (MP to be administered to
pregnant women instead of dexamethasone), so this study will not be
able to elucidate whether MP and dexamethasone have any differences
in efficacy. However, the results of the clinical study presented here
suggest that MP has a lower NNT than dexamethasone. The potential
higher efficacy of MP needs to be confirmed in larger cohorts. However,
in a recent meta-analysis of randomized studies investigating prolonged

Gene Ontology (GO) analysis method. For each GO term (Ashburner and
Lewis, 2002; Consortium et al., 2004), the number of DE genes annotated
to the term is compared to the number of DE genes expected just by chance.
A p-value is computed using the hypergeometric distribution (Draghici
et al., 2003; Draghici, 2011) and corrected with FDR and Bonferroni. We
also used an intelligent pruning approach inspired by the elim and weight
pruning methods (Alexa et al., 2006). The algorithm constructs a custom
cut through the GO hierarchy by starting with the most specific nodes and
calculating their p-value with all genes assigned directly to each such node.
If a node is significant, it is reported as such. If the node is not significant,
the genes associated to the given node are propagated to its direct ancestors
and a p-value is calculated for each of those. See Supplementary Materials
for full details.
Pathway analysis method. The pathways analysis was performed
using the Impact Analysis method (Draghici et al., 2007; Tarca et al.,
2009a; Khatri et al., 2007). The impact analysis uses two types of
evidence: i) the over-representation of differentially expressed (DE) genes
in a given pathway and ii) the perturbation of that pathway computed
by propagating the measured expression changes across the pathway
topology. These aspects are captured by two independent probability
values, pORA and pAcc, that are then combined in a unique pathwayspecific p-value. More details are provided in the Supplementary Materials
and elsewhere (Draghici et al., 2007; Tarca et al., 2009b).
Putative mechanism inference. The impact analysis allows the
computation of the perturbation at the level of every gene on every pathway.
Putative mechanisms are identified as sequences of pathway signals for
which the measured gene expression changes are consistent with the
sequence of events described by the pathway. An example would be
the chemokine-chemokine receptor-JAK-STAT sequence identified on the
Chemokine Signaling Pathway in Fig. 2. This approach is able to identify
candidates for potentially active mechanisms on existing pathways and has
also been shown to have an increased accuracy (Nguyen et al., 2019).
The prediction of upstream Chemicals, Drugs, Toxicants (CDTs)
is based on two types of information: i) the enrichment of DE genes
from the experiment and ii) a network of interactions from the Advaita
Knowledge Base (AKB v1910, www.advaitabio.com). The network is
a directed graph in which the source node represents either a chemical
substance or compound, a drug, or a toxicant (CDT). We focused our work
on FDA-approved drugs that could be repurposed. The edges represent
known increase or decrease expression effects that these CDTs have on
various genes. The analysis considers the hypothesis that a drug could
revert the measured gene expression changes. This analysis is related but
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corticosteroid treatment in non-viral ARDS, methylprednisolone treatment
achieved a reduction in duration of mechanical ventilation and mortality
superior to that of dexamethasone or hydrocortisone (Meduri et al., 2020).
We also looked at other drugs that have already been proposed
as repurposing candidates for COVID-19 including: chloroquine,
hydroxychloroquine, erythromycin, prednisone, ibuprofen, ritonavir,
aspirin, and clopidogrel. None of these was predicted to be effective
in reverting SARS-CoV2 gene expression changes (see Supplementary
Materials).
In summary, we describe the inflammatory pathways associated
with the cytokine storm found in COVID-19 patients and describe the
characterization of the potential effective therapeutic approaches that, by
targeting these pathways could effectible reduce the hyper-inflammatory
response responsible for the development of ARDS, a main cause of
mortality in COVID-19 patients. Clinical results confirmed the efficacy
of the in silico prediction that indicated MP could improve outcomes in
severe COVID-19.
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6 Conclusion
This paper presents an approach for drug repurposing based on identifying
drugs that could revert gene expression changes associated with most
perturbed biological processes and pathways. Results from a clinical study
undertaken in a cohort of 213 patients in a multi-center hospital system
confirmed the efficacy of the in silico prediction that indicated MP could
improve outcomes in severe COVID-19. This prediction is also supported
by the results of independent clinical studies with the same drug undertaken
in Italy (173 patients) and Spain (85 patients). The drug repurposing
approach described here, as well as the drugs identified, might be important
for any future pandemic involving hyper-inflammation.
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substantially different from existing drug repurposing approaches, such
as (Sirota et al., 2011; Peyvandipour et al., 2020; Saberian et al., 2019).
More details are included in Supplementary Materials.
Clinical Validation. We evaluated the MP protocol with a single
pretest, single post-test quasi-experiment from March 12-March 27, 2020
at a 5 hospital health system in Michigan. Patients were compared before
and after implementation of the MP protocol on March 20th. The clinical
characteristics of the patients are shown in Table S2. The primary endpoint
was 30 day all-cause mortality.
The methylprednisolone protocol. Patients with PCR confirmed
COVID-19 who required 4 liters or more of oxygen per minute on
admission, or who had escalating oxygen requirements from baseline,
were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day
in 2 divided doses for 3 days. Patients who required ICU admission were
eligible to extend the IV methylprednisolone course to a maximum of 7
days at the discretion of the medical team. Institutional guidelines also
recommended hydroxychloroquine 400 mg twice daily for 2 doses on day
1, followed by 200 mg twice daily on days 2–5.
Statistical Analysis of clinical data. Survival analysis was performed
using the Kaplan-Meier method and log-rank test. More details about the
statistical analysis and characteristics of the patient population are included
in the Supplementary Materials.
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